vaccination

Seven mass vaccination sites open in England

pharmafile | January 11, 2021 | News story | Sales and Marketing COVID-19, UK, Vaccine 

Seven mass vaccination centres have opened in England today as the government works to vaccinate as many people as possible by February.

The sites set up across the country include London’s ExCel Centre, Manchester Tennis and Football Centre, and Epsom Downs Racecourse in Surrey.

A number of GPs, hospitals, and pharmacies will also begin offering the vaccine to the public later this week – bringing the number of places in the UK that people can access the vaccine to around 1200.

Health Minister Matt Hancock said: “Through our vaccine delivery plan we have already provided a first dose to more than 1.2 million people in England and we are mobilising the government, NHS and the armed forces as part of a massive national effort.

“The vaccination centres are an important milestone and will help accelerate the rollout further.”

Full list of mass vaccination sites in England:

  • The ExCel centre, London
  • Epsom Downs racecourse, Surrey
  • Robertson House, Stevenage
  • Centre for Life, Newcastle
  • The Etihad Tennis and Football Centre, Manchester
  • Ashton Gate stadium, Bristol
  • Millennium Point, Birmingham 

The roll-out of vaccines across these new sites is part of the government’s mission to offer jabs to 13 million people – including all over-80s – by mid-February, in a bid to curb rising coronavirus cases and prevent the country’s hospitals from being overwhelmed.

The UK has so far approved three COVID-19 vaccines for use; Pfizer and BioNTech’s, Oxford University and AstraZeneca’s, and, mostly recently, Moderna’s.

Darcy Jimenez

Related Content

Gilead’s Veklury recommended by NICE for COVID-19 treatment

Gilead Sciences has announced that the National Institute of Health and Care Excellence (NICE) has …

NICE expands access to Paxlovid for 1.4 million people at risk of severe COVID-19

The National Institute for Health and Care Excellence (NICE) has announced that it has expanded …

GSK shares new data for RSV vaccine Arexvy

GSK announced positive results from its phase 3 trial which assessed the immune response and …

Latest content